Prometheus Biosciences

Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA .

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Precision IBD is a Biotechnology company and operator of a drug development precision medicine company intended to develop therapeutics for inflammatory bowel diseases.

Merck

Shares of Merck are down roughly 4% this year, with a market value of roughly $270 billion, making it the third largest pharmaceutical company based in the U.S.

Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Prometheus Biosciences, Inc. (NASDAQ: RXDX) to Merck for $200.00 per share in cash is fair to Prometheus shareholders. Halper Sadeh encourages Prometheus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Promethe.

RXDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Prometheus Biosciences, Inc. Is Fair to Shareholders

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Prometheus Biosciences, Inc. (NasdaqGS: RXDX) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Prometheus will receive $200.00 in cash for each share of Prometheus that they own. KSF is seeking to determine whether this consideration and the process that led to.

PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX

Amgen

Seagen

Horizon Pharma

Reports the FTC could block Amgen's takeover of Horizon reverberated across biotech stocks on Tuesday, with HZNP stock's crash leading the way. The post Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover appeared first on Investor's Business Daily.

Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover

Does Prometheus Biosciences, Inc. (RXDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?

Momentive Global

NEW YORK , May 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Momentive Global Inc. (NASDAQ: MNTV)'s  sale to Symphony Technology Group for $9.46 per share. If you are a Momentive shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTV, RXDX

Prometheus Biosciences, Inc. (RXDX) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.82 per share a year ago.

Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates

- Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 - - Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 -

Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Prometheus Biosciences, Inc. (NasdaqGS: RXDX) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Prometheus will receive $200.00 in cash for each share of Prometheus that they own.

PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX

Merck plans to acquire Prometheus for $10.8 billion in an all-cash deal. The deal will add Prometheus' lead candidate, immunology drug PRA023, to Merck's pipeline.

Why Prometheus Biosciences Stock Is Skyrocketing This Week

Merck (known as MSD outside the United States and Canada) and Prometheus Biosciences recently announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to buy Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion.

Why Merck Is Buying Prometheus Biosciences For About $10.8 Billion

Prometheus Biosciences, Inc. (RXDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?

Roivant Sciences Ltd

Roivant Sciences shares took off on the news that Merck is acquiring Prometheus Biosciences in a $10.8 billion deal as investors placed their bets on which of the two companies could be first to bring to market their promising bowel disease drug candidate.   The acquisition adds Prometheus' monoclonal antibody treatment PRA023 being developed for ulcerative colitis (UC), Crohn's disease, and systematic sclerosis-associated interstitial lung disease to Merck's drug pipeline.

Roivant Sciences shares spike on Merck-Prometheus Biosciences deal

Merck is facing the LOE on Keytruda before the end of the decade, which makes up more than 35% of the company's revenue. The company has an impressive portfolio of assets, but its pipeline is sparse and its valuation is higher.

Merck's Prometheus Acquisition Is A Step In The Right Direction

Prometheus' lead therapy treats ulcerative colitis and a variety of autoimmune disorders. Merck is looking to supplement its immunology portfolio.

Why Shares of Prometheus Biosciences Are Soaring Monday

Merck & Co.'s $10.8 billion acquisition of Prometheus Biosciences Inc., which it announced Sunday, is a strategic positive that will help the drug company diversify its portfolio and reduce the risk of an overreliance on its cancer drug Keytruda, analysts said Monday.

Merck's $10.8 billion takeover of Prometheus is a good strategic move that gives it a foothold in immunology

Prometheus Biosciences Inc (NASDAQ: RXDX) opened about 70% up on Monday after Merck & Co Inc (NYSE: MRK) said it will buy the biotechnology company for $10.8 billion.

Biotech stock Prometheus Biosciences opened 70% up today: here's why

Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio. Prometheus' stock is up 70%.

Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck

Merck is acquiring Prometheus Bio in a well-timed $10.8 billion deal ahead of Keytruda's patent loss. The news sent RXDX stock flying Monday.

Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom

Prometheus Biosciences (NASDAQ: RXDX ) stock surged almost 70% after agreeing to be bought by Merck (NYSE: MRK ) for $10.8 billion in cash. The agreement values Prometheus at $200 per share.

RXDX Stock Alert: The $10.8 Billion Reason Prometheus Biosciences Is Surging Today

XPeng

Stock markets were poised to rise slightly on Monday morning. XPeng shares moved sharply higher after the automaker released details about its new production platform.

XPeng Is Charging Higher, but This Biotech Stock Is Monday's Biggest Winner

Prometheus' PRA023 drug can add 15% to 30% to Merck's long-term earnings once approved, according to Citi analysts.

Merck's $10.8 Billion Prometheus Deal Has Citi Analysts Bullish

Prometheus Biosciences (NASDAQ: RXDX ) stock is on the rise Monday after the company revealed an acquisition deal with Merck (NYSE: MRK ). The deal has Merck offering a total of $10.8 billion to acquire Prometheus Biosciences.

Why Is Prometheus Biosciences (RXDX) Stock Up 70% Today?

State Street

Here are some of the biggest movers on Monday:

Prometheus Biosciences, XPeng and State Street are among the stocks on the move

MILWAUKEE, April 17, 2023 /PRNewswire/ -- Ademi LLP is investigating Prometheus (NASDAQ: RXDX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.

News for Prometheus Biosciences Stock (RXDX)